Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human Chorionic Gonadotropin Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS

NCT03252223
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Healthy, Anovulation, Hyperandrogenism
Interventions
Recombinant Follicle Stimulating Hormone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 9, 2026, 1:31 AM EDT
Recruiting Phase 2 Interventional

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

NCT06440850
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Biospecimen Collection, Cobimetinib, Computed Tomography, Diagnostic Imaging, I-131 Uptake Test, Iodine I-131, Magnetic Resonance Imaging, Positron Emission Tomography, Recombinant Thyrotropin Alfa, Ultrasound Imaging, Vemurafenib
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 9, 2026, 1:31 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

NCT05343572
View directory record Official record
Conditions
Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Interventions
Plerixafor
Drug
Lead sponsor
Hugh Taylor
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Orange, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

NCT02145247
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
hCG
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF

NCT01687712
View directory record Official record
Conditions
Infertility
Interventions
AFOLIA, Gonal-f® RFF
Drug
Lead sponsor
Fertility Biotech AG
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Tempe, Arizona • Encino, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 9, 2026, 1:31 AM EDT
Not listed Not applicable Interventional

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

NCT04447872
View directory record Official record
Conditions
Infertility, Diminished Ovarian Reserve, IVF
Interventions
Timing of injectable gonadotropins
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 9, 2026, 1:31 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Natural Versus Programmed Frozen Embryo Transfer (NatPro)

NCT04551807
View directory record Official record
Conditions
Pregnancy Related, Pre-Eclampsia
Interventions
Modified natural cycle, Programmed cycle
Procedure
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
788 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
15
States / cities
San Francisco, California • Sunnyvale, California • Orange, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 9, 2026, 1:31 AM EDT
Terminated Not applicable Interventional

PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer

NCT06074055
View directory record Official record
Conditions
Infertility, Female
Interventions
FET Protocol
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 53 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Basking Ridge, New Jersey • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 9, 2026, 1:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion

NCT02179944
View directory record Official record
Conditions
Undesired Pregnancy
Interventions
Not listed
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

NCT00839319
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, placebo hCG (no active ingredient), hCG (human chorionic gonadotropin), Testosterone gel
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

NCT02525029
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pregnyl®
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 76 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 9, 2026, 1:31 AM EDT
Withdrawn Phase 2 Interventional

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364
View directory record Official record
Conditions
Stroke
Interventions
NTx™-265: rhCG, then rEPO, Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 9, 2026, 1:31 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Detection of Urinary Human Chorionic Gonadotropin (hCG)

NCT05458778
View directory record Official record
Conditions
Pregnancy Detection
Interventions
Daily test with urine by the product
Device
Lead sponsor
Quanovate Tech Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Ramon, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 9, 2026, 1:31 AM EDT
Terminated Phase 1Phase 2 Interventional

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

NCT05123040
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 9, 2026, 1:31 AM EDT
Not listed No phase listed Observational

Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

NCT01009723
View directory record Official record
Conditions
Preterm Delivery
Interventions
Not listed
Lead sponsor
Esoterix Genetic Laboratories, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Westborough, Massachusetts • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

NCT02310919
View directory record Official record
Conditions
Infertility
Interventions
Low dose hCG plus FSH co-trigger, Standard dose of hCG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 9, 2026, 1:31 AM EDT
Terminated Phase 2 Interventional Results available

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00938314
View directory record Official record
Conditions
Stroke
Interventions
human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2011 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF

NCT01986374
View directory record Official record
Conditions
Infertility
Interventions
HCG is introduced
Drug
Lead sponsor
Servy Massey Fertility Insititute
Other
Eligibility
21 Years to 47 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)

NCT00747617
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
recombinant human chorionic gonadotropin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

NCT02427529
View directory record Official record
Conditions
HCG
Interventions
Human Chorionic Gonadotropin, Placebo, Low calorie diet
Drug · Other
Lead sponsor
Dr. Emma's Corporation
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Colts Neck, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 9, 2026, 1:31 AM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

NCT02069808
View directory record Official record
Conditions
Egg Donation
Interventions
Follistim, Ganirelix, Menotropins, Leuprolide, Transvaginal ultrasound guided needle aspiration of oocytes
Drug · Procedure
Lead sponsor
Michigan Reproductive Medicine
Other
Eligibility
18 Years to 28 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bloomfield Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 9, 2026, 1:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.

NCT00223860
View directory record Official record
Conditions
Hypogonadism, Spinal Cord Injury
Interventions
Human chorionic gonadotropin (hCG), Luteinizing hormone releasing hormone (LHRH)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2008 · Synced Sep 9, 2026, 1:31 AM EDT
Terminated Not applicable Interventional

Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

NCT04852029
View directory record Official record
Conditions
Infertility, Female
Interventions
Low dose hCG
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 46 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 9, 2026, 1:31 AM EDT